Bolte G, Seilmeier W, Wieser H, Holm K, Beuermann K, Newport B, Stern M
University Children's Hospital, Tuebingen, Germany.
Pediatr Res. 1999 Dec;46(6):666-70. doi: 10.1203/00006450-199912000-00010.
In pathogenesis of celiac disease, the significance of prolamin peptide interactions with enterocytes is controversial. Changes in cellular metabolism induced by gliadin peptides, as well as uptake and presentation by enterocytes, are discussed. We analyzed peptide binding to enterocytic membranes as a potential key event. Binding capacities of brush border membranes isolated from small intestinal biopsies of untreated (n = 49) and treated celiac patients on a gluten-free diet (n = 30), as well as control subjects (n = 43), were measured with a dot blot chemiluminescence assay. Synthetic gliadin peptides comprising amino acid position 8-19 (G XIV) and 30-41 (G XI) of alpha-gliadins, a peptic-tryptic digest of gliadin (PT-GLI), and a synthetic zein peptide were used. Comparing treated celiac patients with controls, we observed significantly enhanced membrane-binding of PT-GLI [mean 122.4 densitometric units/microg (95% confidence interval 116.0-128.9) vs 108.9 (102.1-115.7)] and of zein peptide [50.2 (38.4-61.9) vs 28.8 (13.4-44.2)], but only slightly increased binding of the synthetic gliadin peptides G XIV [65.5 (60.6-70.5) vs 62.4 (56.3-68.5) and G XI [75.2 (69.8-80.6) vs 65.9 (55.2-76.5)]. Independent of patient group, membrane-binding capacities for celiac-active gliadin peptides exceeded those of the zein peptide. Thus, interaction of gliadin peptides with the apical enterocytic membrane was not found exclusively in celiac disease. Furthermore, increased binding capacities in treated celiac disease were not confined to celiac-active peptides. Quantitative differences in gliadin peptide binding as a primary characteristic in celiac disease might contribute to pathogenetic effects exerted on small intestinal epithelial cells.
在乳糜泻的发病机制中,醇溶蛋白肽与肠上皮细胞相互作用的意义存在争议。本文讨论了麦醇溶蛋白肽诱导的细胞代谢变化,以及肠上皮细胞的摄取和呈递。我们分析了肽与肠细胞膜的结合,将其作为一个潜在的关键事件。采用斑点印迹化学发光分析法,测定了未经治疗的乳糜泻患者(n = 49)、采用无麸质饮食治疗的乳糜泻患者(n = 30)以及对照受试者(n = 43)的小肠活检标本中分离出的刷状缘膜的结合能力。使用了包含α-醇溶蛋白氨基酸位置8 - 19(G XIV)和30 - 41(G XI)的合成醇溶蛋白肽、醇溶蛋白的胃蛋白酶-胰蛋白酶消化物(PT-GLI)以及一种合成玉米醇溶蛋白肽。将治疗后的乳糜泻患者与对照受试者进行比较,我们观察到PT-GLI的膜结合显著增强[平均光密度单位/微克为122.4(95%置信区间116.0 - 128.9),而对照为108.9(102.1 - 115.7)],玉米醇溶蛋白肽的膜结合也显著增强[50.2(38.4 - 61.9),而对照为28.8(13.4 - 44.2)],但合成醇溶蛋白肽G XIV的结合仅略有增加[65.5(60.6 - 70.5),而对照为62.4(56.3 - 68.5)],合成醇溶蛋白肽G XI的结合也仅略有增加[75.2(69.8 - 80.6),而对照为65.9(55.2 - 76.5)]。与患者组无关,乳糜泻活性醇溶蛋白肽的膜结合能力超过了玉米醇溶蛋白肽。因此,醇溶蛋白肽与顶端肠细胞膜的相互作用并非仅见于乳糜泻。此外,治疗后的乳糜泻患者结合能力的增加并不局限于乳糜泻活性肽。醇溶蛋白肽结合的定量差异作为乳糜泻的主要特征,可能有助于对小肠上皮细胞产生致病作用。